Epoch Biosciences has made available 300 assays targeting SNPs linked with certain cancer populations. These validated real-time PCR assays, identified by the National Cancer Institute, are based on Epoch’s MGB Eclipse probe systems, and were developed with members of NCI’s Cancer Genome Anatomy Project.
Epoch claims that each assay has been functionally tested using a panel of 102 human genomic DNAs specified by the NCI and “verified to yield 100 percent concordance” with genotype calls made by sequencing. Epoch is selling the assays in three order sizes — 500, 1,500, and 5,000 reactions. They can be run on any existing RT-PCR instrument using commercially available PCR reagents, Epoch said.
U.S. Genomics has launched its Trilogy platform for direct detection and quantitation of individual DNA, RNA, and protein molecules without the need for amplification. The company said the first applications will enable researchers to measure microRNA and siRNA and screen samples against a panel of “all known” small RNAs. Trilogy can also validate and characterize specific microRNAs and siRNAs of interest, U.S. Genomics said.
Celera subsidiary Paracel has released version 2.0 of AGENT, or Automated Genotyping Tool, which is targeted at research labs. The software is designed to increase the efficiency of genotyping and mutation discovery by handling trace file datasets. The software uses TraceTuner MX algorithms for base calling and quality value assignment. TraceTuner MX is optimized for heterozygous and mixed bases and can distinguish between noise peaks and low-level mixed bases in pooled samples and viral samples.